Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Viemed Healthcare (VMD) Cash & Equivalents (2018 - 2025)

Viemed Healthcare (VMD) has disclosed Cash & Equivalents for 6 consecutive years, with $13.5 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Cash & Equivalents fell 23.03% year-over-year to $13.5 million, compared with a TTM value of $13.5 million through Dec 2025, down 23.03%, and an annual FY2025 reading of $13.5 million, down 23.03% over the prior year.
  • Cash & Equivalents was $13.5 million for Q4 2025 at Viemed Healthcare, up from $11.1 million in the prior quarter.
  • Across five years, Cash & Equivalents topped out at $31.2 million in Q2 2021 and bottomed at $7.3 million in Q1 2024.
  • Average Cash & Equivalents over 5 years is $18.2 million, with a median of $17.2 million recorded in 2022.
  • The sharpest move saw Cash & Equivalents soared 269.81% in 2021, then tumbled 68.96% in 2024.
  • Year by year, Cash & Equivalents stood at $28.4 million in 2021, then plummeted by 40.46% to $16.9 million in 2022, then decreased by 24.09% to $12.8 million in 2023, then skyrocketed by 36.62% to $17.5 million in 2024, then fell by 23.03% to $13.5 million in 2025.
  • Business Quant data shows Cash & Equivalents for VMD at $13.5 million in Q4 2025, $11.1 million in Q3 2025, and $20.0 million in Q2 2025.